Kristie L. Kahl

An expert in relapsed/refractory follicular lymphoma discusses the approval of tazemetostat as a treatment and reviews the phase 2 clinical trial data.

Javier L. Munoz, MD, MS, FACP, describes the current third-line treatment options available for relapsed/refractory follicular lymphoma.

Preliminary data from the phase 1b GO30103 study indicated that the combination of tiragolumab plus atezolizumab may have promise in patients with heavily pretreated metastatic esophageal cancer.

Dr. Lee Schwartzberg comments on unmet needs in the treatment of early-stage HR+ [hormone receptor-positive] breast cancer.

Current recommendations for conducting genomic testing in patients with HR+ [hormone receptor-positive] breast cancer, as outlined by the NCCN clinical practice guidelines.

Dr. Lee Schwartzberg highlights recent changes to the NCCN guidelines in terms of guidance for genomic testing in HR-positive breast cancer based on updates to the RxPONDER trial and data supporting the use of the Breast Cancer Index.

Common scenarios for which genomic testing is recommended to aid in treatment decisions for patients with hormone receptor-positive breast cancer.

Lee Schwartzberg, MD, FACP, of West Cancer Center & Research Institute, discusses the role of genomic testing in hormone receptor-positive breast cancer and compares information provided by various assays approved for use.

A specialist explains the factors considered when it comes to choosing treatments for patients with relapsed/refractory follicular lymphoma, and the clinical endpoints to look for.

Javier L. Munoz, MD, MS, FACP, describes the effects of R/R FL and discusses the current treatment options available.

An overview of predictive and prognostic biomarkers used by breast oncologists to aid in adjuvant treatment decisions for HR-positive disease, as outlined by the NCCN guidelines.

The rationale for treating patients with early stage HR-positive breast cancer with extended adjuvant therapy based on lessons learned through clinical trial evidence and real-world practice.

Dr. Daniel Ahn discusses the implications of postoperative ctDNA testing for decision-making in early stage CRC.

At the 18-month follow-up, the CAR T-cell therapy led to early, deep, and durable responses with a manageable safety profile in patients with relapsed/refractory multiple myeloma.

After almost 5 years of follow-up, results strongly support upfront daratumumab with lenalidomide and dexamethasone as a new standard of care for patients with transplant-ineligible newly diagnosed multiple myeloma.

The addition of lenalidomide to rituximab continued to improve survival outcomes with durable responses among patients with indolent B-cell non-Hodgkin lymphomas and mantle cell lymphomas.

Treatment with the off-the-shelf, full-size BCMA X CD3 bi-specific antibody appeared well tolerated with promising efficacy among patients with relapsed/refractory multiple myeloma.

For men with asymptomatic or mildly symptomatic mCRPC, using bone-protecting agents during treatment with radium-223 plus enzalutamide controlled the risk for fractures.

Follow-up data from the phase 3 TIVO-3 trial that were reported at the 2021 ASCO Annual Meeting serve to further support the use of tivozanib versus standard-of-care sorafenib in patients with metastatic renal cell carcinoma who have failed on prior therapy.

The CAR T-cell product idecabtagene vicleucel in patients with heavily pretreated multiple myeloma continued to show benefit of therapy at a median follow-up of 24.8 months.

Awaited outcomes of the phase 3 OUTBACK trial presented at the 2021 ASCO Annual Meeting do not indicate benefit of adjuvant chemotherapy for patients with cervical cancer.

A review of safety and efficacy data demonstrated by the IMpower133 clinical trial of atezolizumab plus chemotherapy as first-line treatment for extensive-stage small cell lung cancer.

Sameh Gaballa, MD, focuses on unmet needs and the future of the treatment landscape for follicular lymphoma.

A key opinion leader reviews the role of PI3K kinase inhibitors in the third-line or later settings for the treatment of follicular lymphoma.

A discussion regarding typical response rates to frontline therapy for extensive-stage small cell lung cancer and considerations for incorporating an immunotherapy agent into first-line treatment.

An overview of current gaps in treatment for patients with extensive-stage, or metastatic small cell lung cancer.

Dr Benjamin Levy describes common treatment approaches for patients with limited-stage small cell lung cancer and extensive-stage small cell lung cancer.

A leader in diagnosis and management of CRC reviews the role of MRD testing in early stage CRC.

Benjamin Levy, MD, of the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, comments on risk factors and the prognosis for patients diagnosed with small cell lung cancer.

In this special edition of the “Oncology Peer Review On-The-Go” podcast, CancerNetwork spoke with Reshma L. Mahtani, DO, about genomic testing to optimize treatment outcomes in HR-positive breast cancer.